Tarsus to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its management team's upcoming participation in two major investor conferences in February 2025. The company will engage in fireside chats at:

• The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET

• The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET

Interested parties can access a live webcast through the events section of the Tarsus website. Replay recordings will be made available within 48 hours of each event and will remain accessible for a time.

IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences:

• The Guggenheim SMID Cap Biotech Conference on Thursday, February 6^th, at 6:00 a.m. PT / 9:00 a.m. ET
• The Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Wednesday, February 12^th, at 7:00 a.m. PT / 10:00 a.m. ET

A live webcast and additional information can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When is Tarsus Pharmaceuticals (TARS) presenting at the Guggenheim SMID Cap Biotech Conference in 2025?

Tarsus Pharmaceuticals will present at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, 2025, at 6:00 a.m. PT / 9:00 a.m. ET.

What time is Tarsus (TARS) presenting at the Oppenheimer Healthcare Conference in February 2025?

Tarsus will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, 2025, at 7:00 a.m. PT / 10:00 a.m. ET.

How can investors access the Tarsus (TARS) investor conference presentations in February 2025?

Investors can access a live webcast of the presentations through the events section of the Tarsus website.

How long will the replay of Tarsus (TARS) February 2025 investor conferences be available?

The replay will be available on the Tarsus website within 48 hours of each event and will be archived for a time.